In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition

Both formulations showed broad-spectrum anti-HPV activity in vitro (IC50: 1-20 ng/ml), significantly decreasing HPV PsV infection in the mouse model (−2 h/+2 h, p < 0.0001). PC-515 protected better than Divine 9 in the −24 h dosing regimen (p < 0.0001) and comparable to Divine 9 in the −2 h/+2 h regimen (p = 0.9841). PC-515 retained full activity in the murine model when PsV solutions contained human SP. The durable, potential broad-spectrum anti-HPV activity of CG formulations in the presence of SP supports their further development to prevent HPV acquisition.